FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016205218> ?p ?o ?g. }

• W2016205218 endingPage "410" @default.
• W2016205218 startingPage "403" @default.
• W2016205218 abstract "Background/Aims We showed previously that amino acid (aa) substitutions in the HCV core region (HCV-CR) are predictors of non-virological response (NVR) to peginterferon (PEG-IFN) plus ribavirin (RBV) therapy. Here, we determined the predictive factors of sustained virological response (SVR) and early virologic response (EVR) to this treatment. Methods We evaluated the response to 48-week PEG-IFN-RBV therapy in 114 Japanese adults infected with HCV genotype 1b and determined the predictors of EVR and SVR. Results EVR was achieved by 70% and SVR by 45% of patients. 64% of patients who achieved EVR also showed SVR, while none of non-EVR achieved SVR. Multivariate analysis identified low-density lipoprotein cholesterol (LDL-C) (⩾86 mg/dl), aa substitutions in HCV-CR (double-wild-type; arginine at aa 70/leucine at aa 91), gamma-glutamyl transpeptidase (GGT) (<109 IU/l), RBV dose (⩾11.0 mg/kg), and leukocyte count (⩾4500/mm3) as significant determinants of EVR, and aa substitutions in HCV-CR (double-wild-type), LDL-C (⩾86 mg/dl), male gender, ICG R15 (<10%), GGT (<109 IU/l), and RBV dose (⩾11.0 mg/kg) as determinants of SVR. Prediction of response to therapy based on combination of these factors had high sensitivity, specificity, positive, and negative predictive values. Conclusions Our study identified aa substitutions in the core region and serum LDL-C as predictors of response to PEG-IFN-RBV therapy in Japanese patients infected with HCV genotype 1b. We showed previously that amino acid (aa) substitutions in the HCV core region (HCV-CR) are predictors of non-virological response (NVR) to peginterferon (PEG-IFN) plus ribavirin (RBV) therapy. Here, we determined the predictive factors of sustained virological response (SVR) and early virologic response (EVR) to this treatment. We evaluated the response to 48-week PEG-IFN-RBV therapy in 114 Japanese adults infected with HCV genotype 1b and determined the predictors of EVR and SVR. EVR was achieved by 70% and SVR by 45% of patients. 64% of patients who achieved EVR also showed SVR, while none of non-EVR achieved SVR. Multivariate analysis identified low-density lipoprotein cholesterol (LDL-C) (⩾86 mg/dl), aa substitutions in HCV-CR (double-wild-type; arginine at aa 70/leucine at aa 91), gamma-glutamyl transpeptidase (GGT) (<109 IU/l), RBV dose (⩾11.0 mg/kg), and leukocyte count (⩾4500/mm3) as significant determinants of EVR, and aa substitutions in HCV-CR (double-wild-type), LDL-C (⩾86 mg/dl), male gender, ICG R15 (<10%), GGT (<109 IU/l), and RBV dose (⩾11.0 mg/kg) as determinants of SVR. Prediction of response to therapy based on combination of these factors had high sensitivity, specificity, positive, and negative predictive values. Our study identified aa substitutions in the core region and serum LDL-C as predictors of response to PEG-IFN-RBV therapy in Japanese patients infected with HCV genotype 1b." @default.
• W2016205218 created "2016-06-24" @default.
• W2016205218 creator A5010056452 @default.
• W2016205218 creator A5014470642 @default.
• W2016205218 creator A5015577892 @default.
• W2016205218 creator A5022738328 @default.
• W2016205218 creator A5024325916 @default.
• W2016205218 creator A5026182073 @default.
• W2016205218 creator A5031710130 @default.
• W2016205218 creator A5044932403 @default.
• W2016205218 creator A5057057637 @default.
• W2016205218 creator A5066429603 @default.
• W2016205218 creator A5084522512 @default.
• W2016205218 creator A5089243471 @default.
• W2016205218 date "2007-03-01" @default.
• W2016205218 modified "2023-10-15" @default.
• W2016205218 title "Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels" @default.
• W2016205218 cites W1550484024 @default.
• W2016205218 cites W1907126157 @default.
• W2016205218 cites W1963710185 @default.
• W2016205218 cites W1971792395 @default.
• W2016205218 cites W1979065789 @default.
• W2016205218 cites W1986505810 @default.
• W2016205218 cites W1989375145 @default.
• W2016205218 cites W1992239172 @default.
• W2016205218 cites W1993974155 @default.
• W2016205218 cites W2012929232 @default.
• W2016205218 cites W2013847854 @default.
• W2016205218 cites W2014012653 @default.
• W2016205218 cites W2027545702 @default.
• W2016205218 cites W2036306822 @default.
• W2016205218 cites W2047480444 @default.
• W2016205218 cites W2049495897 @default.
• W2016205218 cites W2053702303 @default.
• W2016205218 cites W2054586386 @default.
• W2016205218 cites W2057211436 @default.
• W2016205218 cites W2057318017 @default.
• W2016205218 cites W2073293272 @default.
• W2016205218 cites W2075660007 @default.
• W2016205218 cites W2084742492 @default.
• W2016205218 cites W2085388521 @default.
• W2016205218 cites W2088089910 @default.
• W2016205218 cites W2090002359 @default.
• W2016205218 cites W2101177020 @default.
• W2016205218 cites W2113552969 @default.
• W2016205218 cites W2116570352 @default.
• W2016205218 cites W2126365434 @default.
• W2016205218 cites W2127685726 @default.
• W2016205218 cites W2141216632 @default.
• W2016205218 cites W2150757291 @default.
• W2016205218 cites W2152503132 @default.
• W2016205218 cites W2155820299 @default.
• W2016205218 cites W2159954692 @default.
• W2016205218 cites W2162234181 @default.
• W2016205218 cites W2168911689 @default.
• W2016205218 cites W4251925572 @default.
• W2016205218 doi "https://doi.org/10.1016/j.jhep.2006.09.019" @default.
• W2016205218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17126448" @default.
• W2016205218 hasPublicationYear "2007" @default.
• W2016205218 type Work @default.
• W2016205218 sameAs 2016205218 @default.
• W2016205218 citedByCount "260" @default.
• W2016205218 countsByYear W20162052182012 @default.
• W2016205218 countsByYear W20162052182013 @default.
• W2016205218 countsByYear W20162052182014 @default.
• W2016205218 countsByYear W20162052182015 @default.
• W2016205218 countsByYear W20162052182016 @default.
• W2016205218 countsByYear W20162052182017 @default.
• W2016205218 countsByYear W20162052182018 @default.
• W2016205218 countsByYear W20162052182020 @default.
• W2016205218 countsByYear W20162052182021 @default.
• W2016205218 countsByYear W20162052182023 @default.
• W2016205218 crossrefType "journal-article" @default.
• W2016205218 hasAuthorship W2016205218A5010056452 @default.
• W2016205218 hasAuthorship W2016205218A5014470642 @default.
• W2016205218 hasAuthorship W2016205218A5015577892 @default.
• W2016205218 hasAuthorship W2016205218A5022738328 @default.
• W2016205218 hasAuthorship W2016205218A5024325916 @default.
• W2016205218 hasAuthorship W2016205218A5026182073 @default.
• W2016205218 hasAuthorship W2016205218A5031710130 @default.
• W2016205218 hasAuthorship W2016205218A5044932403 @default.
• W2016205218 hasAuthorship W2016205218A5057057637 @default.
• W2016205218 hasAuthorship W2016205218A5066429603 @default.
• W2016205218 hasAuthorship W2016205218A5084522512 @default.
• W2016205218 hasAuthorship W2016205218A5089243471 @default.
• W2016205218 hasConcept C104317684 @default.
• W2016205218 hasConcept C126322002 @default.
• W2016205218 hasConcept C135763542 @default.
• W2016205218 hasConcept C203014093 @default.
• W2016205218 hasConcept C2522874641 @default.
• W2016205218 hasConcept C2776408679 @default.
• W2016205218 hasConcept C2776455275 @default.
• W2016205218 hasConcept C2776999253 @default.
• W2016205218 hasConcept C2780040827 @default.
• W2016205218 hasConcept C55493867 @default.
• W2016205218 hasConcept C71924100 @default.
• W2016205218 hasConcept C86803240 @default.
• W2016205218 hasConcept C90924648 @default.

• next